

*The Proposition 65 List is updated periodically, so please keep the latest version. For the latest information, please refer to the following website of the California OEHHA: <https://oehha.ca.gov/proposition-65/proposition-65-list>

STATE OF CALIFORNIA
ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT
SAFE DRINKING WATER AND TOXIC ENFORCEMENT ACT OF 1986

PROPOSITION 65 LIST OF CARCINOGENS OR REPRODUCTIVE TOXICANTS
29-Dec-23

The Safe Drinking Water and Toxic Enforcement Act of 1986 (Health and Safety Code section 25249.5 et seq.), also known as In the Listing Mechanism column, "AB" denotes authoritative bodies, "SQE" denotes State's Qualified Experts, "FR" denotes formally

Chemical	Type of Toxicity	Listing Mechanism	CAS No.	Date Listed	NSRL or MADL (µg/day) ^a
A-alpha-C (2-Amino-9H-pyrido[2,3-b]indole)	cancer	A.B.	26148-68-5	1-Jan-90	<u>2</u>
Abiraterone acetate	Developmental, female, male	FR	154229-18-2	8-Apr-16	
Acetaldehyde	cancer	SQE	75-07-0	1-Apr-88	90 (inhalation)
Acetamide	cancer	A.B.	60-35-5	1-Jan-90	<u>10</u>
Acetazolamide	developmental	FR	59-66-5	20-Aug-99	
Acetochlor	cancer	SQE	34256-82-1	1-Jan-89	
Acetohydroxamic acid	developmental	FR	546-88-3	1-Apr-90	
2-Acetylaminofluorene	cancer	SQE	53-96-3	1-Jul-87	<u>0.2</u>
Acifluorfen sodium	cancer	A.B.	62476-59-9	1-Jan-90	
Acrylamides	cancer	A.B.	79-06-1	1-Jan-90	0.2
Acrylamides	Developmental, male	A.B.	79-06-1	25-Feb-11	<u>140</u>
Acrylonitrile	cancer	FR	107-13-1	1-Jul-87	0.7
Actinomycin D [Basis for listing changed effectiveness February 22, 2013]	cancer	FR	50-76-0	1-Oct-89	<u>0.00008</u>
Actinomycin D	developmental	FR	50-76-0	1-Oct-92	
AF-2;[2-(2-furyl)-3-(5-nitro-2-furyl)]acrylamide	cancer	SQE	3688-53-7	1-Jul-87	<u>3</u>
Aflatoxins	cancer	SQE	---	1-Jan-88	
Alachlor	cancer	SQE	15972-60-8	1-Jan-89	
Alcoholic beverages	cancer	LC	---	29-Apr-11	
Alcoholic beverages, when associated with alcohol abuse	cancer	SQE	---	1-Jul-88	
Aldrin	cancer	SQE	309-00-2	1-Jul-88	0.04
All-trans retinoic acid	developmental	SQE	302-79-4	1-Jan-89	
Aloe vera, non-decolorized whole leaf extract	cancer	LC	---	4-Dec-15	
Alprazolam	developmental	FR	28981-97-7	1-Jul-90	
Altretamine	Developmental, male	FR	645-05-6	20-Aug-99	
Amantadine hydrochloride	developmental	FR	665-66-7	27-Feb-01	
Amikacin sulfate	developmental	FR	39831-55-5	1-Jul-90	
2-Aminoanthraquinone	cancer	LC	117-79-3	1-Oct-89	<u>20</u>
p-Aminoazobenzene	cancer	A.B.	60-09-3	1-Jan-90	
o-Aminoazotoluene	cancer	SQE	97-56-3	1-Jul-87	<u>0.2</u>
4-Aminobiphenyl	cancer	LC	92-67-1	27-Feb-87	<u>0.03</u>
2-Amino-4-chlorophenol	cancer	LC	95-85-2	13-Sep-19	
1-Amino-2,4-dibromoanthraquinone	cancer	A.B.	81-49-2	26-Aug-97	
3-Amino-9-ethylcarbazole hydrochloride	cancer	SQE	6109-97-3	1-Jul-89	<u>9</u>
2-Aminofluorene	cancer	SQE	153-78-6	29-Jan-99	
Aminoglycoside	developmental	FR	125-84-8	1-Jul-90	
Aminoglycosides	developmental	FR	---	1-Oct-92	
1-Amino-2-methylanthraquinone	cancer	LC	82-28-0	1-Oct-89	<u>5</u>
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole	cancer	SQE	712-68-5	1-Jul-87	<u>0.04</u>
4-Amino-2-nitrophenol	cancer	SQE	119-34-6	29-Jan-99	
Aminophthalmology	Developmental, female	SQE	54-62-6	1-Jul-87	
Aminodarone hydrochloride	Developmental, female, male	FR	19774-82-4	26-Aug-97	
Amitraz	developmental	A.B.	33089-61-1	30-Mar-99	
Amitrole	cancer	SQE	61-82-5	1-Jul-87	<u>0.7</u>
Amoxapine	developmental	FR	14028-44-5	15-May-98	
Amsacrine	cancer	LC	51264-14-3	7-Aug-09	

Anabolic steroids	Female, Male	FR	---	1-Apr-90	
Analgesic mixtures containing Phenacetin	cancer	LC	---	27-Feb-87	
Androstenedione	cancer	<u>A.B.</u>	63-05-8	3-May-11	
Angiotensin converting enzyme (ACE) inhibitors	developmental	FR	---	1-Oct-92	
Aniline	cancer	A.B.	62-53-3	1-Jan-90	100
Aniline hydrochloride	cancer	<u>A.B.</u>	142-04-1	15-May-98	
o-Anisidine	cancer	SQE	90-04-0	1-Jul-87	<u>5</u>
o-Anisidine hydrochloride	cancer	SQE	134-29-2	1-Jul-87	<u>7</u>
Anisindione	developmental	FR	117-37-3	1-Oct-92	
Anthracene	cancer	<u>LC</u>	120-12-7	11-Aug-23	
Anthraquinone	cancer	<u>A.B.</u>	84-65-1	28-Sep-07	
Antimony oxide (Antimony trioxide)	cancer	A.B.	1309-64-4	1-Oct-90	
Aramite	cancer	SQE	140-57-8	1-Jul-87	<u>20</u>
Areca nuts	cancer	<u>LC</u>	---	3-Feb-06	
Aristolochic acids	cancer	<u>LC</u>	---	9-Jul-04	
Arsenic (inorganic arsenic compounds)	cancer	LC	--	27-Feb-87	0.06 (inhalation) 10 (except inhalation)
Arsenic (inorganic oxides)	developmental	<u>SQE</u>	---	1-May-97	
Asbestos	cancer	LC	1332-21-4	27-Feb-87	100 fibers/day (inhalation)
Aspirin (NOTE: It is especially important not to use aspirin during the last three months of pregnancy, unless specifically directed to do so by a physician because it may cause problems in the unborn child or complications during delivery.)	Developmental, female	SQE	50-78-2	1-Jul-90	
Atenolol	developmental	<u>FR</u>	29122-68-7	26-Aug-97	
Atrazine	Developmental, female	<u>A.B.</u>	1912-24-9	15-Jul-16	<u>100 (oral)</u>
Auramine	cancer	SQE	492-80-8	1-Jul-87	<u>0.8</u>
Auranofin	developmental	FR	34031-32-8	29-Jan-99	
Avermectin B1 (Abamectin)	developmental	<u>A.B.</u>	71751-41-2	3-Dec-10	<u>4.4</u>
Azacitidine	cancer	A.B.	320-67-2	1-Jan-92	
Azaserine	cancer	SQE	115-02-6	1-Jul-87	<u>0.06</u>
Azathioprine	cancer	LC	446-86-6	27-Feb-87	<u>0.4</u>
Azathioprine	developmental	FR	446-86-6	1-Sep-96	
Azobenzene	cancer	A.B.	103-33-3	1-Jan-90	6
Barbiturates	developmental	FR	---	1-Oct-92	
Beclomethasone dipropionate	developmental	<u>FR</u>	5534-09-8	15-May-98	
Benomyl	Developmental, male	SQE	17804-35-2	1-Jul-91	
Benthiavalicarb-isopropyl	cancer	<u>A.B.</u>	177406-68-7	1-Jul-08	
Benz[a]anthracene	cancer	SQE	56-55-3	1-Jul-87	<u>0.033 (oral)</u>
Benzene	cancer	LC	71-43-2	27-Feb-87	<u>6.4 (oral) 13 (inhalation)</u>
Benzene	Developmental, male	<u>SQE</u>	71-43-2	26-Dec-97	<u>24 (oral) 49 (inhalation)</u>
Benidine [and its salts]	cancer	LC	92-87-5	27-Feb-87	0.001
Benidine-based dyes	cancer	FR	---	1-Oct-92	
Benzodiazepines	developmental	FR	---	1-Oct-92	
Benzo[b]fluoranthene	cancer	SQE	205-99-2	1-Jul-87	<u>0.096 (oral)</u>
Benzo[j]fluoranthene	cancer	SQE	205-82-3	1-Jul-87	<u>0.11 (oral)</u>
Benzo[k]fluoranthene	cancer	SQE	207-08-9	1-Jul-87	
Benzofuran	cancer	A.B.	271-89-6	1-Oct-90	<u>1.1</u>
Benzophenone	cancer	<u>LC</u>	119-61-9	22-Jun-12	
Benzo[a]pyrene	cancer	SQE	50-32-8	1-Jul-87	0.06
Benzotrichloride	cancer	SQE	98-07-7	1-Jul-87	
Benzphetamine hydrochloride	developmental	FR	5411-22-3	1-Apr-90	
Benzyl chloride	cancer	A.B.	100-44-7	1-Jan-90	4
Benzyl violet 4B	cancer	SQE	1694-09-3	1-Jul-87	<u>30</u>
Beryllium and beryllium compounds	cancer	SQE	---	1-Oct-87	
Beryllium					0.1
Beryllium oxide					0.1
Beryllium sulfate					0.0002
Betel quid with tobacco	cancer	A.B.	---	1-Jan-90	
Betel quid without tobacco	cancer	<u>LC</u>	---	3-Feb-06	
Bevacizumab	Developmental, female	<u>FR</u>	216974-75-3	8-Mar-19	
2,2-Bis(bromomethyl)-1,3-propanediol	cancer	A.B.	3296-90-0	1-May-96	
Bis(2-chloroethyl)ether	cancer	SQE	111-44-4	1-Apr-88	0.3

N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornapazine)	cancer	LC	494-03-1	27-Feb-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	cancer	SQE	154-93-8	1-Jul-87	
Bischloroethyl nitrosourea (BCNU) (Carmustine)	developmental	FR	154-93-8	1-Jul-90	
Bis(chloromethyl)ether	cancer	LC	542-88-1	27-Feb-87	0.02
Bis(2-chloro-1-methylethyl)ether, technical grade	cancer	<u>SQE</u>	---	29-Oct-99	
Bisphenol A (BPA)	female	<u>SQE</u>	80-05-7	11-May-15	3 (dermal exposure from solid materials)
Bisphenol A (BPA)	developmental	A.B.	80-05-7	18-Dec-20	
Bisphenol S (BPS)	female	<u>SQE</u>	80-09-1	29-Dec-23	
Bitumens, extracts of steam-refined and air refined	cancer	A.B.	---	1-Jan-90	
Black fern	cancer	A.B.	---	1-Jan-90	
Bromacil lithium salt	developmental	<u>A.B.</u>	53404-19-6	18-May-99	
Bromacil lithium salt	male	<u>SQE</u>	53404-19-6	17-Jan-03	
Bromate	cancer	<u>A.B.</u>	15541-45-4	31-May-02	
Bromochloroacetic acid	cancer	<u>A.B.</u>	5589-96-8	6-Apr-10	0.7
1-Bromo-3-chloropropane	cancer	LC	109-70-6	27-Jan-23	
Bromodichloroacetic acid	cancer	<u>A.B.</u>	71133-14-7	29-Jul-16	0.95
Bromodichloromethane	cancer	A.B.	75-27-4	1-Jan-90	5
Bromoethane	cancer	<u>A.B.</u>	74-96-4	22-Dec-00	96
Bromoform	cancer	A.B.	75-25-2	1-Apr-91	64
1-Bromopropane (1-BP)	cancer	<u>A.B.</u>	106-94-5	5-Aug-16	
1-Bromopropane (1-BP)	Developmental, female, male	<u>A.B.</u>	106-94-5	7-Dec-04	
2-Bromopropane (2-BP)	cancer	LC	75-26-3	11-Aug-23	
2-Bromopropane (2-BP)	Female, Male	<u>A.B.</u>	75-26-3	31-May-05	
Bromoxynil	developmental	FR	1689-84-5	1-Oct-90	
Bromoxynil octanoate	developmental	<u>A.B.</u>	1689-99-2	18-May-99	
Butabarbital sodium	developmental	FR	143-81-7	1-Oct-92	
1,3-Butadiene	cancer	SQE	106-99-0	1-Apr-88	0.4
1,3-Butadiene	Developmental, female, male	<u>A.B.</u>	106-99-0	16-Apr-04	
1,4-Butanediol dimethanesulfonate (Busulfan)	cancer	LC	55-98-1	27-Feb-87	
1,4-Butanediol dimethanesulfonate (Busulfan)	developmental	SQE	55-98-1	1-Jan-89	
Butylated hydroxyanisole	cancer	A.B.	25013-16-5	1-Jan-90	4000
Butyl benzyl phthalate (BBP) ^d	developmental	<u>A.B.</u>	85-68-7	2-Dec-05	1200 (oral)
1-Butyl glycidyl ether	cancer	LC	2426-08-6	27-Jan-23	
n-Butyl glycidyl ether Delisted April 4, 2014 [Click here for the basis for delisting]	male	LC	2426-08-6	7-Aug-09	
beta-Butyrolactone	cancer	SQE	3068-88-0	1-Jul-87	0.7
Cacodylic acid	cancer	A.B.	75-60-5	1-May-96	
Cadmium	Developmental, male	<u>SQE</u>	---	1-May-97	4.1 (oral)
Cadmium and cadmium compounds	cancer	SQE	---	1-Oct-87	
Cadmium					0.05 (inhalation)
Cannabis (marijuana) smoke	developmental	<u>SQE</u>	---	3-Jan-20	
Caffeic acid	cancer	A.B.	331-39-5	1-Oct-94	
Captafol	cancer	<u>SQE</u>	2425-06-1	1-Oct-88	5
Captan	cancer	A.B.	133-06-2	1-Jan-90	300
Carbamazepine	developmental	FR	298-46-4	29-Jan-99	
Carbaryl	cancer	<u>A.B.</u>	63-25-2	5-Feb-10	
Carbaryl [Basis for listing changed effectiveness December 27, 2013]	Developmental, female, male	<u>A.B.</u>	63-25-2	7-Aug-09	
Carbazole	cancer	A.B.	86-74-8	1-May-96	4.1
Carbon black (airborne, unbound particles of respirable size)	cancer	<u>A.B.</u>	1333-86-4	21-Feb-03	
Carbon-black extracts	cancer	A.B.	---	1-Jan-90	
Carbon disulfide	Developmental, female, male	SQE	75-15-0	1-Jul-89	
Carbon monoxide	developmental	SQE	630-08-0	1-Jul-89	
Carbon tetrachloride	cancer	SQE	56-23-5	1-Oct-87	5
Carboplatin	developmental	FR	41575-94-4	1-Jul-90	
N-Carboxymethyl-N-nitrosourea	cancer	<u>SQE</u>	60391-92-6	25-Jan-02	0.7
Catechol	cancer	<u>A.B.</u>	120-80-9	15-Jul-03	
Ceramic fibers (airborne particles of respirable size)	cancer	A.B.	---	1-Jul-90	

Certain combined chemotherapy for lymphomas	cancer	LC	---	27-Feb-87	
Chenodiol	developmental	FR	474-25-9	1-Apr-90	
Chloral	cancer	LC	75-87-6	13-Sep-13	
Chloral hydrate	cancer	LC	302-17-0	13-Sep-13	
Chlorambucil	cancer	LC	305-03-3	27-Feb-87	0.002
Chlorambucil	developmental	SQE	305-03-3	1-Jan-89	
Chloramphenicol sodium succinate	cancer	FR	982-57-0	27-Sep-13	
Chlorcyclizine hydrochloride	developmental	FR	1620-21-9	1-Jul-87	
Chlordane	cancer	SQE	57-74-9	1-Jul-88	0.5
Chlordecone (Kepone)	cancer	SQE	143-50-0	1-Jan-88	0.04
Chlordecone (Kepone)	developmental	SQE	143-50-0	1-Jan-89	
Chlordiazepoxide	developmental	FR	58-25-3	1-Jan-92	
Chlordiazepoxide hydrochloride	developmental	FR	438-41-5	1-Jan-92	
Chlordimeform	cancer	SQE	6164-98-3	1-Jan-89	
Chlorendic acid	cancer	SQE	115-28-6	1-Jul-89	8
Chlorinated paraffins (Average chain length, C12; approximately 60 percent chlorine by weight)	cancer	SQE	108171-26-2	1-Jul-89	8
<i>p</i> -Chloroaniline	cancer	A.B.	106-47-8	1-Oct-94	1.5
<i>p</i> -Chloroaniline hydrochloride	cancer	A.B.	20265-96-7	15-May-98	1.9
Chloroethane (Ethyl chloride)	cancer	A.B.	75-00-3	1-Jul-90	150
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU)	cancer	SQE	13010-47-4	1-Jan-88	
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)	developmental	FR	13010-47-4	1-Jul-90	
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU)	cancer	SQE	13909-09-6	1-Oct-88	
Chloroform	cancer	SQE	67-66-3	1-Oct-87	20 (oral) 40 (inhalation)
Chloroform [Basis for listing changed effectiveness December 23, 2016]	developmental	SQE	67-66-3	7-Aug-09	
Chloromethyl methyl ether (technical grade)	cancer	LC	107-30-2	27-Feb-87	0.3
3-Chloro-2-methylpropene	cancer	SQE	563-47-3	1-Jul-89	5
1-Chloro-4-nitrobenzene	cancer	SQE	100-00-5	29-Oct-99	
2-Chloronitrobenzene	cancer	LC	88-73-3	13-Sep-19	
4-Chloro- <i>o</i> -phenylenediamine	cancer	SQE	95-83-0	1-Jan-88	40
Chloroprene	cancer	A.B.	126-99-8	2-Jun-00	
2-Chloropropionic acid [Basis for listing changed effectiveness December 20, 2013]	male	SQE	598-78-7	7-Aug-09	
Chlorothalonil	cancer	SQE	1897-45-6	1-Jan-89	41
<i>p</i> -Chloro- <i>o</i> -Toluidine	cancer	A.B.	95-69-2	1-Jan-90	3
<i>p</i> -Chloro- <i>o</i> -toluidine, strong acid salts of	cancer	A.B.	---	15-May-98	
<i>p</i> -Chloro- <i>o</i> -Toluidine hydrochloride					3.3
5-Chloro- <i>o</i> -toluidine and its strong acid salts	cancer	SQE	---	24-Oct-97	
Chlorotrianisene	cancer	FR	569-57-3	1-Sep-96	
<i>p</i> -chloro- α,α,α -trifluorotoluene (<i>para</i> -Chlorobenzotrifluoride, PCBTf)	cancer	A.B.	98-56-6	28-Jun-19	23
Chlorozotocin	cancer	A.B.	54749-90-5	1-Jan-92	0.003
					0.58 (oral and inhalation) 7.2 (dermal)
Chlorpyrifos	developmental	SQE	2921-88-2	15-Dec-17	
Chromium (hexavalent compounds)	cancer	LC	---	27-Feb-87	0.001 (inhalation)
Chromium (hexavalent compounds)	Developmental, female, male	SQE	---	19-Dec-08	8.2 (oral)
Chrysene	cancer	A.B.	218-01-9	1-Jan-90	0.35 (oral)
CI Acid Red 114	cancer	A.B.	6459-94-5	1-Jul-92	
CI Basic Red 9					
monohydrochloride	cancer	SQE	569-61-9	1-Jul-89	3
CI Direct Blue 15	cancer	A.B.	2429-74-5	26-Aug-97	
CI Direct Blue 218	cancer	A.B.	28407-37-6	26-Aug-97	50
CI Disperse Yellow 3	cancer	SQE	2832-40-8	8-Feb-13	
CI Solvent Yellow 14	cancer	A.B.	842-07-9	15-May-98	
Ciclosporin (Cyclosporin A; Cyclosporine)	cancer	A.B.	59865-13-3; 79217-60-0	1-Jan-92	
	cancer, developmental, female, male	FR	113852-37-2	29-Jan-99	
Cinnamyl anthranilate	cancer	SQE	87-29-6	1-Jul-89	200

Cisplatin	cancer	SQE	15663-27-1	1-Oct-88	
Citrus Red No. 2	cancer	LC	6358-53-8	1-Oct-89	
Cladribine	developmental	FR	4291-63-8	1-Sep-96	
Clarithromycin	developmental	FR	81103-11-9	1-May-97	
Clobetasol propionate	Developmental, female	FR	25122-46-7	15-May-98	
Clofibrate	cancer	FR	637-07-0	1-Sep-96	
Clomiphene citrate	cancer	FR	50-41-9	24-May-13	
Clomiphene citrate	developmental	FR	50-41-9	1-Apr-90	
Clorazepate dipotassium	developmental	FR	57109-90-7	1-Oct-92	
CMNP (pyrazachlor)	cancer	A.B.	6814-58-0	25-Aug-15	
Coal-tar pitch	cancer	LC	---	17-Nov-23	
Cobalt metal powder	cancer	A.B.	7440-48-4	1-Jul-92	
Cobalt [II] oxide	cancer	A.B.	1307-96-6	1-Jul-92	
Cobalt sulfate	cancer	LC	10124-43-3	20-May-05	
Cobalt sulfate heptahydrate	cancer	A.B.	10026-24-1	2-Jun-00	
Cocaine	Developmental, female	SQE	50-36-2	1-Jul-89	
Coconut oil diethanolamine condensate (cocamide diethanolamine)	cancer	LC	---	22-Jun-12	
Codeine phosphate	developmental	FR	52-28-8	15-May-98	
Coke oven emissions	cancer	LC	---	27-Feb-87	0.3
Colchicine	Developmental, male	FR	64-86-8	1-Oct-92	
Conjugated estrogens	cancer	LC	---	27-Feb-87	
Conjugated estrogens	developmental	FR	---	1-Apr-90	
Creosotes	cancer	SQE	---	1-Oct-88	
p-Cresidine	cancer	SQE	120-71-8	1-Jan-88	5
Cumene	cancer	A.B.	98-82-8	6-Apr-10	
Cupferron	cancer	SQE	135-20-6	1-Jan-88	3
Cyanazine	developmental	FR	21725-46-2	1-Apr-90	
Cycasin	cancer	SQE	14901-08-7	1-Jan-88	
Cycloate	developmental	A.B.	1134-23-2	19-Mar-99	
Cycloheximide	developmental	FR	66-81-9	1-Jan-89	
Cyclopenta[cd]pyrene	cancer	LC	27208-37-3	29-Apr-11	
Cyclophosphamide (anhydrous)	cancer	LC	50-18-0	27-Feb-87	1
Cyclophosphamide (anhydrous)	Developmental, female, male	SQE - developmental FR - female, male	50-18-0	1-Jan-89	
Cyclophosphamide (hydrate)	cancer	LC	6055-19-2	27-Feb-87	1
Cyclophosphamide (hydrate)	Developmental, female, male	SQE - developmental FR - female, male	6055-19-2	1-Jan-89	
Cyhexatin	developmental	FR	13121-70-5	1-Jan-89	
Cytarabine	developmental	SQE	147-94-4	1-Jan-89	
Cytembena	cancer	A.B.	21739-91-3	15-May-98	
D&C Orange No. 17	cancer	A.B.	3468-63-1	1-Jul-90	
D&C Red No. 8	cancer	A.B.	2092-56-0	1-Oct-90	
D&C Red No. 9	cancer	A.B.	5160-02-1	1-Jul-90	100
D&C Red No. 19	cancer	A.B.	81-88-9	1-Jul-90	
Dicalazine	cancer	SQE	4342-03-4	1-Jan-88	0.01
Dicalazine	developmental	FR	4342-03-4	29-Jan-99	
Daminozide	cancer	A.B.	1596-84-5	1-Jan-90	40
Danazol	developmental	FR	17230-88-5	1-Apr-90	
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone)	cancer	A.B.	117-10-2	1-Jan-92	9
Daunomycin	cancer	SQE	20830-81-3	1-Jan-88	
Daunorubicin hydrochloride	developmental	FR	23541-50-6	1-Jul-90	
2,4-D butyric acid [Click here for the basis for the removal of developmental endpoint, effective June 22, 2001]	male	A.B.	94-82-6	18-Jun-99	910
DDD (Dichlorodiphenyl-dichloroethane)	cancer	SQE	72-54-8	1-Jan-89	2 (DDT, DDE, DDD in combination)
DDE (Dichlorodiphenyl-dichloroethylene)	cancer	SQE	72-55-9	1-Jan-89	2 (DDT, DDE, DDD in combination)
DDT (Dichlorodiphenyl-trichloroethane)	cancer	SQE	50-29-3	1-Oct-87	2 (DDT, DDE, DDD in combination)
o,p'-DDT	Developmental, female, male	A.B.	789-02-6	15-May-98	
p,p'-DDT	Developmental, female, male	A.B.	50-29-3	15-May-98	
DDVP (Dichlorvos)	cancer	SQE	62-73-7	1-Jan-89	2
Demeclocycline hydrochloride (internal use)	developmental	FR	64-73-3	1-Jan-92	

Des-ethyl atrazine (DEA)	Developmental, female	<u>A.B.</u>	6190-65-4	15-Jul-16	<u>100 (oral)</u>
Des-isopropyl atrazine (DIA)	Developmental, female	<u>A.B.</u>	1007-28-9	15-Jul-16	<u>100 (oral)</u>
N,N'-Diacetylbenzidine	cancer	<u>LC</u>	613-35-4	1-Oct-89	
2,4-Diaminoanisole	cancer	<u>FR</u>	615-05-4	1-Oct-90	<u>30</u>
2,4-Diaminoanisole sulfate	cancer	<u>SQE</u>	39156-41-7	1-Jan-88	<u>50</u>
2,4-Diamino-6-chloro-s-triazine (DACT)	Developmental, female	<u>A.B.</u>	3397-62-4	15-Jul-16	<u>100 (oral)</u>
4,4'-Diaminodiphenyl ether (4,4'-Oxydianiline)	cancer	<u>SQE</u>	101-80-4	1-Jan-88	<u>5</u>
2,4-Diaminotoluene	cancer	<u>SQE</u>	95-80-7	1-Jan-88	<u>0.2</u>
Diazepam	developmental	<u>FR</u>	439-14-5	1-Jan-92	
Diazoaminobenzene	cancer	<u>LC</u>	136-35-6	20-May-05	
Diazoxide	developmental	<u>FR</u>	364-98-7	27-Feb-01	
Dibenz[a,h]acridine	cancer	<u>SQE</u>	226-36-8	1-Jan-88	
Dibenz[a,j]acridine	cancer	<u>SQE</u>	224-42-0	1-Jan-88	
Dibenzanthracenes	cancer	<u>SQE</u>	---	26-Dec-14	
Dibenz[a,c]anthracene	cancer	<u>SQE</u>	215-58-7	26-Dec-14	
Dibenz[a,h]anthracene	cancer	<u>SQE</u>	53-70-3	1-Jan-88	<u>0.2</u>
Dibenz[a,j]anthracene	cancer	<u>SQE</u>	224-41-9	26-Dec-14	
7H-Dibenzo[c,g]carbazole	cancer	<u>SQE</u>	194-59-2	1-Jan-88	<u>0.0030 (oral)</u>
Dibenzo[a,e]pyrene	cancer	<u>SQE</u>	192-65-4	1-Jan-88	
Dibenzo[a,h]pyrene	cancer	<u>SQE</u>	189-64-0	1-Jan-88	<u>0.0054 (oral)</u>
Dibenzo[a,i]pyrene	cancer	<u>SQE</u>	189-55-9	1-Jan-88	<u>0.0050 (oral)</u>
Dibenzo[a,l]pyrene	cancer	<u>SQE</u>	191-30-0	1-Jan-88	
Dibromoacetic acid	cancer	<u>A.B.</u>	631-64-1	17-Jun-08	<u>2.8</u>
Dibromoacetonitrile	cancer	<u>A.B.</u>	3252-43-5	3-May-11	
1,2-Dibromo-3-chloropropane (DBCP)	cancer	<u>FR</u>	96-12-8	1-Jul-87	<u>0.1</u>
1,2-Dibromo-3-chloropropane (DBCP) [Basis for listing changed effectiveness November 22, 2013]	male	<u>FR</u>	96-12-8	27-Feb-87	<u>3.1 (oral) 4.3 (inhalation)</u>
2,3-Dibromo-1-propanol	cancer	<u>A.B.</u>	96-13-9	1-Oct-94	
Dichloroacetic acid	cancer	<u>A.B.</u>	79-43-6	1-May-96	<u>17</u>
Dichloroacetic acid	Developmental, male	<u>A.B.</u>	79-43-6	7-Aug-09	
p-Dichlorobenzene	cancer	<u>SQE</u>	106-46-7	1-Jan-89	<u>20</u>
3,3'-Dichlorobenzidine	cancer	<u>SQE</u>	91-94-1	1-Oct-87	<u>0.6</u>
3,3'-Dichlorobenzidine dihydrochloride	cancer	<u>A.B.</u>	612-83-9	15-May-98	
1,1-Dichloro-2,2-bis(p-chlorophenyl)ethylene (DDE)	Developmental, male	<u>A.B.</u>	72-55-9	30-Mar-10	
1,4-Dichloro-2-butene	cancer	<u>A.B.</u>	764-41-0	1-Jan-90	
3,3'-Dichloro-4,4'-diaminodiphenyl ether	cancer	<u>SQE</u>	28434-86-8	1-Jan-88	
1,1-Dichloroethane	cancer	<u>A.B.</u>	75-34-3	1-Jan-90	<u>100</u>
Dichloromethane (Methylene chloride)	cancer	<u>SQE</u>	75-09-2	1-Apr-88	<u>50 200 (inhalation)</u>
1,4-Dichloro-2-nitrobenzene	cancer	<u>LC</u>	89-61-2	13-Sep-19	
2,4-Dichloro-1-nitrobenzene	cancer	<u>LC</u>	611-06-3	13-Sep-19	
Dichlorophene	developmental	<u>A.B.</u>	97-23-4	27-Apr-99	
Dichlorophenamide	developmental	<u>FR</u>	120-97-8	27-Feb-01	
1,2-Dichloropropane	cancer	<u>A.B.</u>	78-87-5	1-Jan-90	<u>9.7</u>
1,3-Dichloro-2-propanol (1,3-DCP)	cancer	<u>SQE</u>	96-23-1	8-Oct-10	
1,3-Dichloropropene	cancer	<u>SQE</u>	542-75-6	1-Jan-89	<u>3.7 (oral and inhalation)</u>
Diclofop-methyl	cancer	<u>A.B.</u>	51338-27-3	6-Apr-10	
Diclofop methyl	developmental	<u>A.B.</u>	51338-27-3	5-Mar-99	
Dicumarol	developmental	<u>FR</u>	66-76-2	1-Oct-92	
Dieldrin	cancer	<u>SQE</u>	60-57-1	1-Jul-88	<u>0.04</u>
Diepoxybutane	cancer	<u>SQE</u>	1464-53-5	1-Jan-88	
Diesel engine exhaust	cancer	<u>A.B.</u>	---	1-Oct-90	
Diethanolamine	cancer	<u>LC</u>	111-42-2	22-Jun-12	
Di(2-ethylhexyl)phthalate (DEHP)	cancer	<u>SQE</u>	117-81-7	1-Jan-88	<u>310</u>
Di(2-ethylhexyl)phthalate (DEHP)	Developmental, male	<u>A.B.</u>	117-81-7	24-Oct-03	
Adult ^b					<u>4200 (intravenous)</u>
Infant boys, age 29 days to 24 months ^b					<u>600 (intravenous)</u>
Neonatal infant boys, age 0 to 28 days ^b					<u>210 (intravenous)</u>
Adult ^b					<u>410 (oral)</u>
Infant boys, age 29 days to 24 months ^b					<u>58 (oral)</u>

Neonatal infant boys, age 0 to 28 days ^b					20 (oral)
1,2-Diethylhydrazine	cancer	SQE	1615-80-1	1-Jan-88	
Diethylstilbestrol (DES)	cancer	LC	56-53-1	27-Feb-87	0.002
Diethylstilbestrol (DES)	developmental	FR	56-53-1	1-Jul-87	
Diethyl sulfate	cancer	SQE	64-67-5	1-Jan-88	
Diflunisal	Developmental, female	FR	22494-42-4	29-Jan-99	
Diglycidyl resorcinol ether (DGRE)	cancer	SQE	101-90-6	1-Jul-89	0.4
Dihydroergotamine mesylate	developmental	FR	6190-39-2	1-May-97	
Dihydrosafrole	cancer	SQE	94-58-6	1-Jan-88	20
Diisodecyl phthalate (DIDP)	developmental	A.B.	68515-49-1/ 26761-40-0	20-Apr-07	2200
Diisononyl phthalate (DINP)	cancer	SQE	---	20-Dec-13	146
Diisopropyl sulfate	cancer	A.B.	2973-10-6	1-Apr-93	
Diltiazem hydrochloride	developmental	FR	33286-22-5	27-Feb-01	
3,3'-Dimethoxybenzidine (o-Dianisidine)	cancer	SQE	119-90-4	1-Jan-88	0.15
3,3'-Dimethoxybenzidine dihydrochloride	cancer	A.B.	20325-40-0	1-Oct-90	0.19
3,3'-Dimethoxybenzidine-based dyes metabolized to 3,3'-dimethoxybenzidine	cancer	A.B.	---	11-Jun-04	
N,N-Dimethylacetamide	cancer	LC	127-19-5	13-Sep-19	
N,N-Dimethylacetamide [Click here for the basis for addition of male reproductive endpoint, effective December 20, 2013]	developmental, male	SQE	127-19-5	21-May-10	
4-Dimethylaminoazobenzene	cancer	SQE	60-11-7	1-Jan-88	0.2
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole	cancer	SQE	55738-54-0	1-Jan-88	2
7,12-Dimethylbenz(a)anthracene	cancer	A.B.	57-97-6	1-Jan-90	0.003
3,3'-Dimethylbenzidine (ortho-Tolidine)	cancer	SQE	119-93-7	1-Jan-88	0.044
3,3'-Dimethylbenzidine-based dyes metabolized to 3,3'-dimethylbenzidine	cancer	A.B.	---	11-Jun-04	
3,3'-Dimethylbenzidine dihydrochloride	cancer	A.B.	612-82-8	1-Apr-92	0.059
Dimethylcarbamoyl chloride	cancer	SQE	79-44-7	1-Jan-88	0.05
N,N-Dimethylformamide	cancer	LC	68-12-2	27-Oct-17	
1,1-Dimethylhydrazine (UDMH)	cancer	LC	57-14-7	1-Oct-89	
1,2-Dimethylhydrazine	cancer	SQE	540-73-8	1-Jan-88	0.001
Dimethyl hydrogen phosphite	cancer	LC	868-85-9	11-Aug-23	
2,6-Dimethyl-N-nitrosomorpholine (DMNM)	cancer	SQE	1456-28-6	8-Feb-13	
Dimethyl sulfate	cancer	SQE	77-78-1	1-Jan-88	
N,N-Dimethyl-p-Toluidine	cancer	A.B.	99-97-8	2-May-14	
Dimethylvinylchloride	cancer	SQE	513-37-1	1-Jul-89	20
Di-n-butyl phthalate (DBP)	Developmental, female, male	A.B.	84-74-2	2-Dec-05	8.7
Di-n-Hexyl phthalate (DnHP)	Female, Male	A.B.	84-75-3	2-Dec-05	2200 (oral)
m-Dinitrobenzene	male	A.B.	99-65-0	1-Jul-90	38
o-Dinitrobenzene	male	A.B.	528-29-0	1-Jul-90	
p-Dinitrobenzene	male	A.B.	100-25-4	1-Jul-90	
3,7-Dinitrofluoranthene	cancer	A.B.	105735-71-5	26-Aug-97	
3,9-Dinitrofluoranthene	cancer	A.B.	22506-53-2	26-Aug-97	
1,3-Dinitropyrene	cancer	LC	75321-20-9	2-Nov-12	
1,6-Dinitropyrene	cancer	A.B.	42397-64-8	1-Oct-90	
1,8-Dinitropyrene	cancer	A.B.	42397-65-9	1-Oct-90	
2,4-Dinitrotoluene	cancer	SQE	121-14-2	1-Jul-88	2
2,4-Dinitrotoluene	male	A.B.	121-14-2	20-Aug-99	
2,6-Dinitrotoluene	cancer	SQE	606-20-2	1-Jul-95	
2,6-Dinitrotoluene	male	A.B.	606-20-2	20-Aug-99	
Dinitrotoluene (technical grade)	Female, Male	A.B.	---	20-Aug-99	
Dinitrotoluene mixture, 2,4-/2,6-	cancer	A.B.	---	1-May-96	
Dinocap	developmental	FR	39300-45-3	1-Apr-90	
Dinoseb	Developmental, male	FR	88-85-7	1-Jan-89	
Di-n-propyl isocinchmeronate (MGK Repellent 326)	cancer	A.B.	136-45-8	1-May-96	
1,4-Dioxane	cancer	SQE	123-91-1	1-Jan-88	30
Diphenylhydantoin (Phenytoin)	cancer	SQE	57-41-0	1-Jan-88	
Diphenylhydantoin (Phenytoin)	developmental	SQE	57-41-0	1-Jul-87	

Diphenylhydantoin (Phenytoin), sodium salt	cancer	SQE	630-93-3	1-Jan-88	
Direct Black 38 (technical grade)	cancer	SQE	1937-37-7	1-Jan-88	0.09
Direct Blue 6 (technical grade)	cancer	SQE	2602-46-2	1-Jan-88	0.09
Direct Brown 95 (technical grade)	cancer	SQE	16071-86-6	1-Oct-88	0.1
Disodium cyanodithioimidocarbonate	developmental	A.B.	138-93-2	30-Mar-99	56 (oral) 170 (oral) as 32% pesticidal formulation
Disperse Blue 1	cancer	A.B.	2475-45-8	1-Oct-90	200
Diuron	cancer	A.B.	330-54-1	31-May-02	
Doxorubicin hydrochloride (Adriamycin)	cancer	SQE	25316-40-9	1-Jul-87	
Doxorubicin hydrochloride (Adriamycin)	Developmental, male	FR	25316-40-9	29-Jan-99	
Doxycycline (internal use)	developmental	FR	564-25-0	1-Jul-90	
Doxycycline calcium (internal use)	developmental	FR	94088-85-4	1-Jan-92	
Doxycycline hyclate (internal use)	developmental	FR	24390-14-5	1-Oct-91	
Doxycycline monohydrate (internal use)	developmental	FR	17086-28-1	1-Oct-91	
Emissions from combustion of coal	cancer	A.B.	---	7-Aug-13	
Emissions from high-temperature unrefined rapeseed oil	cancer	A.B.	---	3-Jan-14	
Endrin	developmental	A.B.	72-20-8	15-May-98	
Environmental tobacco smoke (ETS)	developmental	SQE	---	9-Jun-06	
Epichlorohydrin	cancer	SQE	106-89-8	1-Oct-87	9
Epichlorohydrin	male	A.B.	106-89-8	1-Sep-96	
Epoxiconazole	cancer	A.B.	135319-73-2	15-Apr-11	
Ergotamine tartrate	developmental	FR	379-79-3	1-Apr-90	
Erionite	cancer	SQE	12510-42-8; 66733-21-9	1-Oct-88	
Estradiol 17B	cancer	SQE	50-28-2	1-Jan-88	0.02
Estragole	cancer	SQE	140-67-0	29-Oct-99	
Estrogens, steroids	cancer	LC	---	19-Aug-05	
Estrogen-progestogen (combined) used as menopausal therapy	cancer	LC	---	4-Nov-11	
Estrone	cancer	SQE	53-16-7	1-Jan-88	
Estropipate	cancer, developmental	FR	7280-37-7	26-Aug-97	
Ethinylestradiol	cancer	SQE	57-63-6	1-Jan-88	
Ethionamide	developmental	FR	536-33-4	26-Aug-97	
Ethoprop	cancer	A.B.	13194-48-4	27-Feb-01	
Ethyl acrylate	cancer	SQE	140-88-5	1-Jul-89	
Ethyl alcohol in alcoholic beverages	developmental	SQE	---	1-Oct-87	
Ethylbenzene	cancer	A.B.	100-41-4	11-Jun-04	54 (inhalation) 41 (oral) 700 (oral and inhalation) 6700 (dermal)
Ethyl dipropylthiocarbamate	developmental	A.B.	759-94-4	27-Apr-99	
Ethyl-4,4'-dichlorobenzilate	cancer	A.B.	510-15-6	1-Jan-90	7
Ethylene dibromide	cancer	FR	106-93-4	1-Jul-87	0.2 (oral) 3 (inhalation)
Ethylene dibromide	Developmental, male	A.B.	106-93-4	15-May-98	
Ethylene dichloride (1,2-Dichloroethane)	cancer	SQE	107-06-2	1-Oct-87	10
Ethylene glycol (ingested)	developmental	A.B.	107-21-1	19-Jun-15	8700 (oral)
Ethylene glycol monoethyl ether	Developmental, male	SQE	110-80-5	1-Jan-89	750 (oral) 960 (inhalation)
Ethylene glycol monoethyl ether acetate	Developmental, male	A.B.	111-15-9	1-Jan-93	1100 (oral) 1400 (inhalation)
Ethylene glycol monomethyl ether	Developmental, male	SQE	109-86-4	1-Jan-89	63 (oral)
Ethylene glycol monomethyl ether acetate	Developmental, male	A.B.	110-49-6	1-Jan-93	98 (oral)
Ethyleneimine (Aziridine)	cancer	SQE	151-56-4	1-Jan-88	0.01
Ethylene oxide	cancer	FR	75-21-8	1-Jul-87	2
Ethylene oxide [Basis for listing changed effectiveness November 22, 2013]	female	FR	75-21-8	27-Feb-87	20
Ethylene oxide [Basis for listing changed effectiveness November 22, 2013]	Developmental, male	FR	75-21-8	7-Aug-09	20
Ethylene thiourea	cancer	A.B.	96-45-7	1-Jan-88	20
Ethylene thiourea	developmental	SQE	96-45-7	1-Jan-93	
2-Ethylhexyl acrylate	cancer	LC	103-11-7	17-Dec-21	

Ethyl methanesulfonate	cancer	SQE	62-50-0	1-Jan-88	
Etodolak	Developmental, female	FR	41340-25-4	20-Aug-99	
Etoposide	cancer	LC	33419-42-0	4-Nov-11	
Etoposide	developmental	FR	33419-42-0	1-Jul-90	
Etoposide in combination with cisplatin and bleomycin	cancer	LC	---	4-Nov-11	
Etretinate	developmental	SQE	54350-48-0	1-Jul-87	
Fenoxaprop ethyl	developmental	A.B.	66441-23-4	26-Mar-99	
Fenoxycarb	cancer	A.B.	72490-01-8	2-Jun-00	
Filgrastim	developmental	FR	121181-53-1	27-Feb-01	
Fluazifop butyl	developmental	A.B.	69806-50-4	6-Nov-98	
	Developmental, female	FR	3385-03-3	15-May-98	
Flunisolide	developmental	SQE	51-21-8	1-Jan-89	
Fluorouracil	cancer	LC	---	17-Nov-23	
Fluoro-edenite fibrous amphibole	developmental	FR	76-43-7	1-Apr-90	
Fluoxymesterone	developmental	FR	1172-18-5	1-Oct-92	
Flurazepam hydrochloride	Developmental, female	FR	5104-49-4	20-Aug-99	
Flurbiprofen	developmental	FR	13311-84-7	1-Jul-90	
Flutamide	developmental	FR	80474-14-2	15-May-98	
Fluticasone propionate	developmental	A.B.	69409-94-5	6-Nov-98	
Fluvalinate	cancer	SQE	133-07-3	1-Jan-89	200
Folpet	cancer	SQE	50-00-0	1-Jan-88	40
Formaldehyde (gas)	cancer	SQE	3570-75-0	1-Jan-88	0.3
2-(2-Formylhydrazino)-4-(5-nitro- 2-furyl)thiazole	cancer	A.B.	116355-83-0	14-Nov-03	
Fumonisin B ₁	cancer	A.B.	110-00-9	1-Oct-93	
Furan	cancer	A.B.	67-45-8	1-Jan-90	
Furazolidone	cancer	A.B.	98-00-0	30-Sep-16	
Furfuryl alcohol	cancer	A.B.	60568-05-0	1-Jan-90	20
Furmecyclo	cancer	SQE	79748-81-5	1-Jul-95	
Fusarin C					
Gallium arsenide	cancer	LC	1303-00-0	1-Aug-08	
	Cancer, developmental, male	FR	82410-32-0	26-Aug-97	
Ganciclovir	Developmental, male	FR	107910-75-8	26-Aug-97	
Ganciclovir sodium					
Gasoline engine exhaust (condensates/extracts)	cancer	A.B.	---	1-Oct-90	
Gemfibrozil	cancer	FR	25812-30-0	22-Dec-00	
Gemfibrozil	Female, Male	FR	25812-30-0	20-Aug-99	
Gentian violet (Crystal violet)	cancer	SQE	548-62-9	23-Nov-18	
Glass wool fibers (inhalable and biopersistent)	cancer	A.B.	---	1-Jul-90	
Glu-P-1 (2-Amino-6- methyldipyrido[1,2- a:3',2'- d]imidazole)	cancer	A.B.	67730-11-4	1-Jan-90	0.1
Glu-P-2 (2-Aminodipyrido[1,2- a:3',2'-d]imidazole)	cancer	A.B.	67730-10-3	1-Jan-90	0.5
Glycidaldehyde	cancer	SQE	765-34-4	1-Jan-88	
Glycidol	cancer	A.B.	556-52-5	1-Jul-90	0.54
Glycidyl methacrylate	cancer	LC	106-91-2	27-Jan-23	
Glyphosate	cancer	LC	1071-83-6	7-Jul-17	1100
Goldenseal root powder	cancer	LC	---	4-Dec-15	
	Developmental, female, male	FR	65807-02-5	26-Aug-97	
Goserelin acetate	cancer	A.B.	126-07-8	1-Jan-90	
Griseofulvin					
Gyromitrin (Acetaldehyde methylformylhydrazone)	cancer	SQE	16568-02-8	1-Jan-88	0.07
Halazepam	developmental	FR	23092-17-3	1-Jul-90	
Halobetasol propionate	developmental	FR	66852-54-8	20-Aug-99	
	Developmental, female	FR	52-86-8	29-Jan-99	
Haloperidol	developmental	FR	151-67-7	1-Sep-96	
Halothane	cancer	SQE	2784-94-3	1-Jul-89	10
HC Blue 1	cancer	SQE	76-44-8	1-Jul-88	0.2
Heptachlor	developmental	A.B.	76-44-8	20-Aug-99	
Heptachlor epoxide	cancer	SQE	1024-57-3	1-Jul-88	0.08
Herbal remedies containing plant species of the genus <i>Aristolochia</i>	cancer	LC	---	9-Jul-04	
Hexachlorobenzene	cancer	SQE	118-74-1	1-Oct-87	0.4
Hexachlorobenzene	developmental	SQE	118-74-1	1-Jan-89	

Hexachlorobutadiene	cancer	<u>A.B.</u>	87-68-3	3-May-11	
Hexachlorocyclohexane (technical grade)	cancer	SQE	---	1-Oct-87	0.2
Hexachlorocyclohexane (alpha isomer)					0.3
Hexachlorocyclohexane (beta isomer)					0.5
Hexachlorocyclohexane (gamma isomer)					0.6
Hexachlorodibenzodioxin	cancer	SQE	34465-46-8	1-Apr-88	0.0002
Hexachloroethane	cancer	<u>A.B.</u>	67-72-1	1-Jul-90	<u>20</u>
2,4-Hexadienal (89% trans, trans isomer; 11% cis, trans isomer)	cancer	<u>A.B.</u>	---	4-Mar-05	
Hexafluoroacetone [Basis for listing changed effectiveness June 6, 2014]	developmental, male	<u>LC SQE</u>	684-16-2	1-Aug-08	
Hexamethylphosphoramide	cancer	SQE	680-31-9	1-Jan-88	
Hexamethylphosphoramide	male	<u>A.B.</u>	680-31-9	1-Oct-94	
n-Hexane	male	<u>SQE</u>	110-54-3	15-Dec-17	<u>28,000 (oral) 20,000 (inhalation)</u>
2,5-Hexanedione	male	<u>SQE</u>	110-13-4	4-Dec-15	
Histrelin acetate	developmental	<u>FR</u>	---	15-May-98	
	Developmental, male				
Hydramethylnon	male	<u>A.B.</u>	67485-29-4	5-Mar-99	<u>120 (oral)</u>
Hydrazine	cancer	SQE	302-01-2	1-Jan-88	0.04
Hydrazine sulfate	cancer	SQE	10034-93-2	1-Jan-88	0.2
Hydrazobenzene (1,2-Diphenylhydrazine)	cancer	SQE	122-66-7	1-Jan-88	<u>0.8</u>
Hydrogen cyanide (HCN) and cyanide salts (CN salts)	male	<u>A.B.</u>	---	5-Jul-13	
Cyanide salts that readily dissociate in solution (expressed as cyanide) ^f					<u>9.8</u>
Hydrogen cyanide ^f					<u>10 (oral)</u>
Sodium cyanide ^f					<u>19 (oral)</u>
Potassium cyanide ^f					<u>25 (oral)</u>
1-Hydroxyanthraquinone	cancer	<u>LC</u>	129-43-1	27-May-05	
Hydroxyurea	developmental	<u>FR</u>	127-07-1	1-May-97	
	Developmental, male				
Idarubicin hydrochloride	male	<u>FR</u>	57852-57-0	20-Aug-99	
Ifosfamide	developmental	<u>FR</u>	3778-73-2	1-Jul-90	
Iodine-131	developmental	SQE	10043-66-0	1-Jan-89	
Imazalil	cancer	<u>A.B.</u>	35554-44-0	20-May-11	<u>11</u>
Indeno[1,2,3-cd]pyrene	cancer	SQE	193-39-5	1-Jan-88	
Indium phosphide	cancer	<u>A.B.</u>	22398-80-7	27-Feb-01	
Indium tin oxide	cancer	<u>LC</u>	50926-11-9	19-Mar-21	
IQ (2-Amino-3-methylimidazo[4,5-f] quinoline)	cancer	<u>A.B.</u>	76180-96-6	1-Apr-90	<u>0.5</u>
lprodione	cancer	<u>A.B.</u>	36734-19-7	1-May-96	
			140923-17-7/ 140923-25-7		
lprovalicarb	cancer	<u>A.B.</u>		1-Jun-07	
Iron dextran complex	cancer	SQE	9004-66-4	1-Jan-88	
Isobutyl nitrite	cancer	<u>A.B.</u>	542-56-3	1-May-96	<u>7.4</u>
Isoprene	cancer	<u>A.B.</u>	78-79-5	1-May-96	
Isopyrazam	cancer	<u>A.B.</u>	881685-58-1	24-Jul-12	
Isotretinoin	developmental	SQE	4759-48-2	1-Jul-87	
Isoxaflutole	cancer	<u>A.B.</u>	141112-29-0	22-Dec-00	
Kresoxim-methyl	cancer	<u>A.B.</u>	143390-89-0	3-Feb-12	
Lactofen	cancer	SQE	77501-63-4	1-Jan-89	
Lasiocarpine	cancer	SQE	303-34-4	1-Apr-88	<u>0.09</u>
Lead [Basis for listing changed effectiveness November 22, 2013]	Developmental, female, male	<u>FR</u>	---	27-Feb-87	0.5
Lead and lead compounds	cancer	<u>A.B.</u>	---	1-Oct-92	
Lead					<u>15 (oral)</u>
Lead acetate	cancer	SQE	301-04-2	1-Jan-88	<u>23 (oral)</u>
Lead phosphate	cancer	SQE	7446-27-7	1-Apr-88	<u>58 (oral)</u>
Lead subacetate	cancer	<u>LC</u>	1335-32-6	1-Oct-89	<u>41 (oral)</u>
Leather dust	cancer	<u>LC</u>	---	29-Apr-11	
Leucomalachite green	cancer	<u>LC</u>	129-73-7	21-Apr-23	
	Developmental, female, male				
Leuprolide acetate	female, male	<u>FR</u>	74381-53-6	26-Aug-97	
Levodopa	developmental	<u>FR</u>	59-92-7	29-Jan-99	

Levonorgestrel implants	female	<u>FR</u>	797-63-7	15-May-98	
Lindane and other hexachlorocyclohexane isomers	cancer	<u>LC</u>	---	1-Oct-89	
Linuron	developmental	<u>A.B.</u>	330-55-2	19-Mar-99	<u>460</u>
Lithium carbonate	developmental	<u>FR</u>	554-13-2	1-Jan-91	
Lithium citrate	developmental	<u>FR</u>	919-16-4	1-Jan-91	
Lorazepam	developmental	<u>FR</u>	846-49-1	1-Jul-90	
Lovastatin	developmental	<u>FR</u>	75330-75-5	1-Oct-92	
Lynestrenol	cancer	<u>A.B.</u>	52-76-6	27-Feb-01	
Malathion	cancer	<u>LC</u>	121-75-5	20-May-16	<u>180</u>
Malonaldehyde, sodium salt	cancer	<u>A.B.</u>	24382-04-5	3-May-11	
Mancozeb	cancer	<u>A.B.</u>	8018-01-7	1-Jan-90	
Maneb	cancer	<u>A.B.</u>	12427-38-2	1-Jan-90	
Marijuana smoke	cancer	<u>SQE</u>	---	19-Jun-09	
Me-A-alpha-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole)	cancer	<u>A.B.</u>	68006-83-7	1-Jan-90	<u>0.6</u>
Mebendazole	developmental	<u>FR</u>	31431-39-7	20-Aug-99	
Medroxyprogesterone acetate	cancer	<u>A.B.</u>	71-58-9	1-Jan-90	
Medroxyprogesterone acetate	developmental	<u>FR</u>	71-58-9	1-Apr-90	
Megestrol acetate	cancer	<u>FR</u>	595-33-5	28-Mar-14	
Megestrol acetate	developmental	<u>FR</u>	595-33-5	1-Jan-91	
MelQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline)	cancer	<u>A.B.</u>	77094-11-2	1-Oct-94	<u>0.46</u>
MelQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline)	cancer	<u>A.B.</u>	77500-04-0	1-Oct-94	<u>0.41</u>
Melphalan	cancer	<u>LC</u>	148-82-3	27-Feb-87	<u>0.005</u>
Melphalan	developmental	<u>FR</u>	148-82-3	1-Jul-90	
Menotropins	developmental	<u>FR</u>	9002-68-0	1-Apr-90	
Mepanipyrin	cancer	<u>A.B.</u>	110235-47-7	1-Jul-08	
Meprobamate	developmental	<u>FR</u>	57-53-4	1-Jan-92	
2-Mercaptobenzothiazole	cancer	<u>LC</u>	149-30-4	27-Oct-17	
Mercaptopurine	developmental	<u>FR</u>	6112-76-1	1-Jul-90	
Mercury and mercury compounds	developmental	<u>A.B.</u>	---	1-Jul-90	
Merphalan	cancer	<u>SQE</u>	531-76-0	1-Apr-88	
Mestranol	cancer	<u>SQE</u>	72-33-3	1-Apr-88	
Metam potassium	cancer	<u>A.B.</u>	137-41-7	31-Dec-10	
Methacycline hydrochloride	developmental	<u>FR</u>	3963-95-9	1-Jan-91	
Metham sodium	cancer	<u>A.B.</u>	137-42-8	6-Nov-98	
Metham sodium	developmental	<u>A.B.</u>	137-42-8	15-May-98	<u>290</u>
Methanol	developmental	<u>A.B.</u>	67-56-1	16-Mar-12	<u>47,000 (inhalation) 23,000 (oral)</u>
Methazole	developmental	<u>A.B.</u>	20354-26-1	1-Dec-99	
Methimazole	developmental	<u>FR</u>	60-56-0	1-Jul-90	
Methotrexate	developmental	<u>SQE</u>	59-05-2	1-Jan-89	
Methotrexate sodium	developmental	<u>FR</u>	15475-56-6	1-Apr-90	
5-Methoxypsoralen with ultraviolet A therapy	cancer	<u>SQE</u>	484-20-8	1-Oct-88	
8-Methoxypsoralen with ultraviolet A therapy	cancer	<u>LC</u>	298-81-7	27-Feb-87	
Methyl acrylate	cancer	<u>LC</u>	96-33-3	17-Dec-21	
2-Methylaziridine (Propyleneimine)	cancer	<u>SQE</u>	75-55-8	1-Jan-88	<u>0.028</u>
Methylazoxymethanol	cancer	<u>SQE</u>	590-96-5	1-Apr-88	
Methylazoxymethanol acetate	cancer	<u>SQE</u>	592-62-1	1-Apr-88	
Methyl bromide, as a structural fumigant	developmental	<u>FR</u>	74-83-9	1-Jan-93	<u>810 (inhalation)</u>
Methyl carbamate	cancer	<u>A.B.</u>	598-55-0	15-May-98	<u>160</u>
Methyl chloride	developmental	<u>A.B.</u>	74-87-3	10-Mar-00	
Methyl chloride [Basis for listing changed effectiveness March 7, 2014]	male	<u>A.B.</u>	74-87-3	7-Aug-09	
3-Methylcholanthrene	cancer	<u>A.B.</u>	56-49-5	1-Jan-90	<u>0.03</u>
5-Methylchrysene	cancer	<u>SQE</u>	3697-24-3	1-Apr-88	<u>0.0084 (oral)</u>
4,4'-Methylene bis(2-chloroaniline)	cancer	<u>FR</u>	101-14-4	1-Jul-87	<u>0.5</u>
4,4'-Methylene bis(N,N-dimethyl)benzenamine	cancer	<u>LC</u>	101-61-1	1-Oct-89	<u>20</u>
4,4'-Methylene bis(2-methylaniline)	cancer	<u>SQE</u>	838-88-0	1-Apr-88	<u>0.8</u>
4,4'-Methylenedianiline	cancer	<u>SQE</u>	101-77-9	1-Jan-88	<u>0.4</u>
4,4'-Methylenedianiline dihydrochloride	cancer	<u>SQE</u>	13552-44-8	1-Jan-88	<u>0.6</u>
Methyleugenol	cancer	<u>A.B.</u>	93-15-2	16-Nov-01	
Methylhydrazine and its salts	cancer	<u>A.B.</u>	---	1-Jul-92	

Methylhydrazine					0.058 (oral) 0.090 (inhalation)
Methylhydrazine sulfate					0.18
2-Methylimidazole	cancer	LC	693-98-1	22-Jun-12	
4-Methylimidazole	cancer	A.B.	822-36-6	7-Jan-11	29
Methyl iodide	cancer	SQE	74-88-4	1-Apr-88	
Methyl isobutyl ketone	cancer	LC	108-10-1	4-Nov-11	
Methyl isobutyl ketone (MIBK)	developmental	A.B.	108-10-1	28-Mar-14	
Methyl isocyanate (MIC)	Developmental, female	SQE	624-83-9	12-Nov-10	
Methyl mercury	developmental	SQE	---	1-Jul-87	
Methylmercury compounds	cancer	A.B.	---	1-May-96	
Methyl methanesulfonate	cancer	SQE	66-27-3	1-Apr-88	7
Methyl-n-butyl ketone	developmental	SQE	591-78-6	4-Dec-15	
Methyl-n-butyl ketone [Basis for listing changed effectiveness November 9, 2015]	male	SQE	591-78-6	7-Aug-09	
2-Methyl-1-nitroanthraquinone (of uncertain purity)	cancer	SQE	129-15-7	1-Apr-88	0.2
N-Methyl-N'-nitro-N-nitrosoguanidine	cancer	SQE	70-25-7	1-Apr-88	0.08
N-Methylolacrylamide	cancer	A.B.	924-42-5	1-Jul-90	
N-Methylpyrrolidone	developmental	A.B.	872-50-4	15-Jun-01	3200 (inhalation) 17000 (dermal)
α-Methyl styrene	cancer	LC	98-83-9	2-Nov-12	
Methyltestosterone	developmental	FR	58-18-4	1-Apr-90	
Methylthiouracil	cancer	LC	56-04-2	1-Oct-89	2
Metham	cancer	A.B.	9006-42-2	1-Jan-90	
Metham	developmental	A.B.	9006-42-2	30-Mar-99	
Metronidazole	cancer	SQE	443-48-1	1-Jan-88	
Michler's ketone	cancer	SQE	90-94-8	1-Jan-88	0.8
Midazolam hydrochloride	developmental	FR	59467-96-8	1-Jul-90	
Minocycline hydrochloride (internal use)	developmental	FR	13614-98-7	1-Jan-92	
Mirex	cancer	SQE	2385-85-5	1-Jan-88	0.04
Misoprostol	developmental	FR	59122-46-2	1-Apr-90	
Mitomycin C	cancer	SQE	50-07-7	1-Apr-88	0.00009
Mitoxantrone hydrochloride	cancer	FR	70476-82-3	23-Jan-15	
Mitoxantrone hydrochloride	developmental	FR	70476-82-3	1-Jul-90	
Molinate	Developmental, female, male	A.B.	2212-67-1	11-Dec-09	
Molybdenum trioxide	cancer	LC	1313-27-5	19-Mar-21	
MON 4660 (dichloroacetyl-1-oxa-4-azaspiro(4,5)-decane	cancer	A.B.	71526-07-3	22-Mar-11	
MON 13900 (furilazole)	cancer	A.B.	121776-33-8	22-Mar-11	
3-Monochloropropane-1,2-diol (3-MCPD)	cancer	SQE	96-24-2	8-Oct-10	
Monocrotaline	cancer	SQE	315-22-0	1-Apr-88	0.07
MOPP (vincristine-prednisone-nitrogen mustard-procarbazine mixture)	cancer	LC	113803-47-7	4-Nov-11	
5-(Morpholinomethyl)-3-[(5-nitrofurfuryl-idene)-amino]-2-oxazolidinone	cancer	SQE	139-91-3	1-Apr-88	0.18
Mustard Gas	cancer	LC	505-60-2	27-Feb-87	
MX (3-chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone)	cancer	SQE	77439-76-0	22-Dec-00	0.11
Myclobutanil	Developmental, male	A.B.	88671-89-0	16-Apr-99	
beta-Myrcene	cancer	A.B.	123-35-3	27-Mar-15	
Nabam	developmental	A.B.	142-59-6	30-Mar-99	
Nafarelin acetate	developmental	FR	86220-42-0	1-Apr-90	
Nafenopin	cancer	SQE	3771-19-5	1-Apr-88	
Nalidic acid	cancer	A.B.	389-08-2	15-May-98	28
Naphthalene	cancer	A.B.	91-20-3	19-Apr-02	5.8
1-Naphthylamine	cancer	LC	134-32-7	1-Oct-89	
2-Naphthylamine	cancer	LC	91-59-8	27-Feb-87	0.4
Neomycin sulfate (internal use)	developmental	FR	1405-10-3	1-Oct-92	
Netilmicin sulfate	developmental	FR	56391-57-2	1-Jul-90	
Nickel (Metallic)	cancer	LC	7440-02-0	1-Oct-89	
Nickel acetate	cancer	LC	373-02-4	1-Oct-89	
Nickel carbonate	cancer	LC	3333-67-3	1-Oct-89	
Nickel carbonyl	cancer	SQE	13463-39-3	1-Oct-87	
Nickel carbonyl	developmental	A.B.	13463-39-3	1-Sep-96	
Nickel compounds	cancer	LC	---	7-May-04	
Nickel (soluble compounds)	Developmental, male	SQE	---	26-Oct-18	

Nickel hydroxide	cancer	LC	12054-48-7; 12125-56-3	1-Oct-89	
Nickelocene	cancer	LC	1271-28-9	1-Oct-89	
Nickel oxide	cancer	LC	1313-99-1	1-Oct-89	
Nickel refinery dust from the pyrometallurgical process	cancer	SQE	---	1-Oct-87	0.8
Nickel subsulfide	cancer	SQE	12035-72-2	1-Oct-87	0.4
Nicotine	developmental	FR	54-11-5	1-Apr-90	
Nifedipine	Developmental, female, male	FR	21829-25-4	29-Jan-99	
Nimodipine	developmental	FR	66085-59-4	24-Apr-01	
Niridazole	cancer	SQE	61-57-4	1-Apr-88	
Nitrapyrin [Basis for listing changed effectiveness on November 4, 2015]	cancer	SQE	1929-82-4	5-Oct-05	
Nitrapyrin	developmental	A.B.	1929-82-4	30-Mar-99	
Nitrioltriacetic acid	cancer	SQE	139-13-9	1-Jan-88	100
Nitrioltriacetic acid, trisodium salt monohydrate	cancer	SQE	18662-53-8	1-Apr-89	70
5-Nitroacenaphthene	cancer	SQE	602-87-9	1-Apr-88	6
<i>o</i> -Nitroanisole	cancer	A.B.	91-23-6	1-Oct-92	
<i>para</i> -Nitroanisole	cancer	LC	100-17-4	13-Sep-19	
Nitrobenzene	cancer	A.B.	98-95-3	26-Aug-97	
Nitrobenzene	male	A.B.	98-95-3	30-Mar-10	
4-Nitrobiphenyl	cancer	SQE	92-93-3	1-Apr-88	
6-Nitrochrysene	cancer	A.B.	7496-02-8	1-Oct-90	
Nitrofen (technical grade)	cancer	SQE	1836-75-5	1-Jan-88	9
2-Nitrofluorene	cancer	A.B.	607-57-8	1-Oct-90	
Nitrofurantoin	male	A.B.	67-20-9	1-Apr-91	
Nitrofurazone	cancer	A.B.	59-87-0	1-Jan-90	0.5
1-[(5-Nitrofurfurylidene)-amino]-2- imidazolidinone	cancer	SQE	555-84-0	1-Apr-88	0.4
N-[4-(5-Nitro-2-furyl)-2- thiazolyl]acetamide	cancer	SQE	531-82-8	1-Apr-88	0.5
Nitrogen mustard (Mechlorethamine)	cancer	SQE	51-75-2	1-Jan-88	
Nitrogen mustard (Mechlorethamine)	developmental	SQE	51-75-2	1-Jan-89	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	cancer	SQE	55-86-7	1-Apr-88	
Nitrogen mustard hydrochloride (Mechlorethamine hydrochloride)	developmental	FR	55-86-7	1-Jul-90	
Nitrogen mustard N-oxide	cancer	SQE	126-85-2	1-Apr-88	
Nitrogen mustard N-oxide hydrochloride	cancer	SQE	302-70-5	1-Apr-88	
Nitromethane	cancer	A.B.	75-52-5	1-May-97	39
2-Nitropropane	cancer	SQE	79-46-9	1-Jan-88	
1-Nitropyrene	cancer	A.B.	5522-43-0	1-Oct-90	
4-Nitropyrene	cancer	A.B.	57835-92-4	1-Oct-90	
N-Nitrosodi- <i>n</i> -butylamine	cancer	SQE	924-16-3	1-Oct-87	0.06
N-Nitrosodiethanolamine	cancer	SQE	1116-54-7	1-Jan-88	0.3
N-Nitrosodiethylamine	cancer	SQE	55-18-5	1-Oct-87	0.02
N-Nitrosodimethylamine	cancer	SQE	62-75-9	1-Oct-87	0.04
<i>p</i> -Nitrosodiphenylamine	cancer	SQE	156-10-5	1-Jan-88	30
N-Nitrosodiphenylamine	cancer	SQE	86-30-6	1-Apr-88	80
N-Nitrosodi- <i>n</i> -propylamine	cancer	SQE	621-64-7	1-Jan-88	0.1
N-Nitroso-N-ethylurea	cancer	SQE	759-73-9	1-Oct-87	0.03
N-Nitrosohexamethyleneimine	cancer	SQE	932-83-2	23-Nov-18	
3-(N-Nitrosomethylamino) propionitrile	cancer	A.B.	60153-49-3	1-Apr-90	
4-(N-Nitrosomethylamino)-1-(3- pyridyl)1-butanone	cancer	A.B.	64091-91-4	1-Apr-90	0.014
N-Nitrosomethyl- <i>n</i> -butylamine	cancer	SQE	7068-83-9	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -decylamine	cancer	SQE	75881-22-0	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -dodecylamine	cancer	SQE	55090-44-3	26-Dec-14	
N-Nitrosomethylethylamine	cancer	LC	10595-95-6	1-Oct-89	0.03
N-Nitrosomethyl- <i>n</i> -heptylamine	cancer	SQE	16338-99-1	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -hexylamine	cancer	SQE	28538-70-7	26-Dec-14	
N-Nitrosomethyl- <i>N</i> -nonylamine	cancer	SQE	75881-19-5	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -octylamine	cancer	SQE	34423-54-6	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -pentylamine	cancer	SQE	13256-07-0	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -propylamine	cancer	SQE	924-46-9	26-Dec-14	
N-Nitrosomethyl- <i>n</i> - tetradecylamine	cancer	SQE	75881-20-8	26-Dec-14	
N-Nitrosomethyl- <i>n</i> -undecylamine	cancer	SQE	68107-26-6	26-Dec-14	
N-Nitroso-N-methylurea	cancer	SQE	684-93-5	1-Oct-87	0.006
N-Nitroso-N-methylurethane	cancer	SQE	615-53-2	1-Apr-88	0.006

N-Nitrosomethylvinylamine	cancer	SQE	4549-40-0	1-Jan-88	
N-Nitrosomorpholine	cancer	SQE	59-89-2	1-Jan-88	0.1
N-Nitrososornicotine	cancer	SQE	16543-55-8	1-Jan-88	0.5
N-Nitrosopiperidine	cancer	SQE	100-75-4	1-Jan-88	0.07
N-Nitrosopyrrolidine	cancer	SQE	930-55-2	1-Oct-87	0.3
N-Nitrososarcosine	cancer	SQE	13256-22-9	1-Jan-88	
o-Nitrotoluene	cancer	A.B.	88-72-2	15-May-98	
Nitrous oxide [Basis for listing changed effectiveness November 8, 2013]	Developmental, female	A.B.	10024-97-2	1-Aug-08	
Norethisterone (Norethindrone)	cancer	LC	68-22-4	1-Oct-89	
Norethisterone (Norethindrone)	developmental	FR	68-22-4	1-Apr-90	
Norethisterone acetate (Norethindrone acetate)	developmental	FR	51-98-9	1-Oct-91	
Norethisterone (Norethindrone) /Ethinyl estradiol	developmental	FR	68-22-4/ 57-63-6	1-Apr-90	
Norethisterone (Norethindrone) /Mestranol	developmental	FR	68-22-4/ 72-33-3	1-Apr-90	
Norethynodrel	cancer	A.B.	68-23-5	27-Feb-01	
Norgestrel	developmental	FR	6533-00-2	1-Apr-90	
Ochratoxin A	cancer	A.B.	303-47-9	1-Jul-90	
Oil Orange SS	cancer	SQE	2646-17-5	1-Apr-88	
Oral contraceptives, combined	cancer	LC	---	1-Oct-89	
Oral contraceptives, sequential	cancer	LC	---	1-Oct-89	
Oryzalin	cancer	A.B.	19044-88-3	12-Sep-08	
Oxadiazon	cancer	SQE	19666-30-9	1-Jul-91	
Oxadiazon	developmental	A.B.	19666-30-9	15-May-98	
Oxazepam	cancer	A.B.	604-75-1	1-Oct-94	
Oxazepam	developmental	FR	604-75-1	1-Oct-92	
Oxydemeton methyl	Female, Male	A.B.	301-12-2	6-Nov-98	
Oxymetholone	cancer	SQE	434-07-1	1-Jan-88	
Oxymetholone	developmental	FR	434-07-1	1-May-97	
Oxytetracycline (internal use)	developmental	FR	79-57-2	1-Jan-91	
Oxytetracycline hydrochloride (internal use)	developmental	FR	2058-46-0	1-Oct-91	
Oxythioquinox (Chinomethionat)	cancer	A.B.	2439-01-2	20-Aug-99	
Oxythioquinox (Chinomethionat)	developmental	A.B.	2439-01-2	6-Nov-98	
Paclitaxel	Developmental, female, male	FR	33069-62-4	26-Aug-97	
Palygorskite fibers (> 5µm in length)					
Panfuran S	cancer	A.B.	12174-11-7	28-Dec-99	
Paramethadone	cancer	SQE	794-93-4	1-Jan-88	
Parathion	developmental	FR	115-67-3	1-Jul-90	
Parathion	cancer	LC	56-38-2	20-May-16	
Penicillamine	developmental	FR	52-67-5	1-Jan-91	
pentabromodiphenyl ether mixture [DE-71 (technical grade)]	cancer	A.B.	---	7-Jul-17	
Pentachlorophenol	cancer	A.B.	87-86-5	1-Jan-90	40
Pentachlorophenol and by-products of its synthesis (complex mixture)	cancer	A.B.	---	21-Oct-16	
Pentobarbital sodium	developmental	FR	57-33-0	1-Jul-90	
Pentosan polysulfate sodium	cancer	LC	---	18-Apr-14	
Pentostatin	developmental	FR	53910-25-1	1-Sep-96	
Perfluorononanoic acid (PFNA) and its salts	male	SQE	---	31-Dec-21	
Perfluorooctane sulfonate (PFOS)	developmental	A.B.	1763-23-1	10-Nov-17	
Perfluorooctane sulfonic acid (PFOS) and its salts and transformation and degradation precursors	cancer	SQE	---	24-Dec-21	
Perfluorooctanoic acid (PFOA)	cancer	A.B.	335-67-1	25-Feb-22	
Perfluorooctanoic acid (PFOA)	developmental	A.B.	335-67-1	10-Nov-17	
Pertuzumab	developmental	FR	380610-27-5	27-Jan-17	
Phenacemide	developmental	FR	63-98-9	1-Jul-90	
Phenacetin	cancer	LC	62-44-2	1-Oct-89	300
Phenazopyridine	cancer	SQE	94-78-0	1-Jan-88	4
Phenazopyridine hydrochloride	cancer	SQE	136-40-3	1-Jan-88	5
Phenesterin	cancer	SQE	3546-10-9	1-Jul-89	0.005
Phenobarbital	cancer	A.B.	50-06-6	1-Jan-90	2
Phenolphthalein	cancer	A.B.	77-09-8	15-May-98	
Phenoxybenzamine	cancer	SQE	59-96-1	1-Apr-88	0.2
Phenoxybenzamine hydrochloride	cancer	SQE	63-92-3	1-Apr-88	0.3
Phenprocoumon	developmental	FR	435-97-2	1-Oct-92	
o-Phenylenediamine and its salts	cancer	A.B.	95-54-5	15-May-98	

o-Phenylenediamine					<u>26</u>
o-Phenylenediamine dihydrochloride					<u>44</u>
Phenyl glycidyl ether	cancer	A.B.	122-60-1	1-Oct-90	<u>5</u>
Phenylhydrazine and its salts	cancer	A.B.	---	1-Jul-92	
Phenylhydrazine					<u>1</u>
Phenylhydrazine hydrochloride					<u>1.4</u>
o-Phenylphenate, sodium	cancer	A.B.	132-27-4	1-Jan-90	<u>200</u>
o-Phenylphenol	cancer	A.B.	90-43-7	4-Aug-00	
PhiP(2-Amino-1-methyl-6-phenylimidazol[4,5-b]pyridine)	cancer	A.B.	105650-23-5	1-Oct-94	
Pimozide	Developmental, female	FR	2062-78-4	20-Aug-99	
Pioglitazone	cancer	LC	111025-46-8	18-Apr-14	
Pipobroman	developmental	FR	54-91-1	1-Jul-90	
Pirimicarb	cancer	A.B.	23103-98-2	1-Jul-08	
Plicamycin	developmental	FR	18378-89-7	1-Apr-90	
Polybrominated biphenyls	cancer	SQE	---	1-Jan-88	0.02
Polybrominated biphenyls	developmental	A.B.	---	1-Oct-94	
Polychlorinated biphenyls	cancer	LC	---	1-Oct-89	0.09
Polychlorinated biphenyls	developmental	SQE	---	1-Jan-91	
Polychlorinated biphenyls (containing 60 or more percent chlorine by molecular weight)	cancer	SQE	---	1-Jan-88	
Polychlorinated dibenzo- <i>p</i> -Dioxins	cancer	FR	---	1-Oct-92	
Polychlorinated dibenzofurans	cancer	FR	---	1-Oct-92	
Polygeenan	cancer	SQE	53973-98-1	1-Jan-88	<u>1200</u>
Ponceau MX	cancer	SQE	3761-53-3	1-Apr-88	<u>200</u>
Ponceau 3R	cancer	SQE	3564-09-8	1-Apr-88	<u>40</u>
Potassium bromate	cancer	A.B.	7758-01-2	1-Jan-90	<u>1</u>
Potassium dimethyldithiocarbamate	developmental	A.B.	128-03-0	30-Mar-99	<u>720</u>
Pravastatin sodium	developmental	FR	81131-70-6	3-Mar-00	
Prednisolone sodium phosphate	developmental	FR	125-02-0	20-Aug-99	
Primidone	cancer	A.B.	125-33-7	20-Aug-99	
Procarbazine	cancer	SQE	671-16-9	1-Jan-88	0.05
Procarbazine hydrochloride	cancer	SQE	366-70-1	1-Jan-88	<u>0.06</u>
Procarbazine hydrochloride	developmental	FR	366-70-1	1-Jul-90	
Procymidone	cancer	A.B.	32809-16-8	1-Oct-94	
Progesterone	cancer	SQE	57-83-0	1-Jan-88	
Pronamide	cancer	A.B.	23950-58-5	1-May-96	
Propachlor	cancer	A.B.	1918-16-7	27-Feb-01	
1,3-Propane sultone	cancer	SQE	1120-71-4	1-Jan-88	<u>0.3</u>
Propargite	cancer	A.B.	2312-35-8	1-Oct-94	
Propargite	developmental	A.B.	2312-35-8	15-Jun-99	
Propazine	Developmental, female	A.B.	139-40-2	15-Jul-16	<u>100 (oral)</u>
beta-Propionate	cancer	SQE	57-57-8	1-Jan-88	<u>0.05</u>
Propoxur	cancer	A.B.	114-26-1	11-Aug-06	
Propylene glycol mono- <i>t</i> -butyl ether	cancer	A.B.	57018-52-7	11-Jun-04	
Propylene oxide	cancer	SQE	75-56-9	1-Oct-88	
Propylthiouracil	cancer	SQE	51-52-5	1-Jan-88	<u>0.7</u>
Propylthiouracil	developmental	FR	51-52-5	1-Jul-90	
Pulegone	cancer	LC	89-82-7	18-Apr-14	
Pymetrozine	cancer	A.B.	123312-89-0	22-Mar-11	
Pyridine	cancer	A.B.	110-86-1	17-May-02	
Pyrimethamine	developmental	FR	58-14-0	29-Jan-99	
Quazepam	developmental	FR	36735-22-5	26-Aug-97	
Quinoline and its strong acid salts	cancer	SQE	---	24-Oct-97	
Quizalofop-ethyl	male	SQE	76578-14-8	24-Dec-99	<u>590</u>
Radionuclides	cancer	SQE	---	1-Jul-89	
Reserpine	cancer	LC	50-55-5	1-Oct-89	<u>0.06</u>
Residual (heavy) fuel oils	cancer	A.B.	---	1-Oct-90	
Resmethrin	cancer	A.B.	10453-86-8	1-Jul-08	
Resmethrin	developmental	A.B.	10453-86-8	6-Nov-98	

Retinol/retinyl esters, when in daily dosages in excess of 10,000 IU, or 3,000 retinol equivalents. (NOTE: Retinol/retinyl esters are required and essential for maintenance of normal reproductive function. The recommended daily level during pregnancy is 8,000 IU.)					
	developmental	SQE	---	1-Jul-89	
Ribavirin	developmental	FR	36791-04-5	1-Apr-90	
Ribavirin	male	FR	36791-04-5	27-Feb-01	
Riddelliine	cancer	LC	23246-96-0	3-Dec-04	
Rifampin	Developmental, female	FR	13292-46-1	27-Feb-01	
Safrole	cancer	SQE	94-59-7	1-Jan-88	3
Salted fish, Chinese-style	cancer	LC	---	29-Apr-11	
Secobarbital sodium	developmental	FR	309-43-3	1-Oct-92	
Sedaxane	cancer	A.B.	874967-67-6	1-Jul-16	
Selenium sulfide	cancer	LC	7446-34-6	1-Oct-89	
Sermorelin acetate	developmental	FR	---	20-Aug-99	
Shale oils	cancer	A.B.	68308-34-9	1-Apr-90	
Silica, crystalline (airborne particles of respirable size)	cancer	SQE	---	1-Oct-88	
Silicon carbide whiskers	cancer	LC	---	17-Nov-23	
Simazine	Developmental, female	A.B.	122-34-9	15-Jul-16	100 (oral)
Sodium dimethyldithiocarbamate	developmental	A.B.	128-04-1	30-Mar-99	23 (oral) 58 (oral) as a 40% pesticidal formulation
Sodium fluoroacetate	male	A.B.	62-74-8	6-Nov-98	
soots, tars, and mineral oils (untreated and mildly treated oils and used engine oils)	cancer	LC	---	27-Feb-87	
Spirodiclofen	cancer	A.B.	148477-71-8	8-Oct-10	
Spironolactone	cancer	FR	52-01-7	1-May-97	
Stanozolol	cancer	FR	10418-03-8	1-May-97	
Sterigmatocystin	cancer	SQE	10048-13-2	1-Apr-88	0.02
Streptomycin sulfate	developmental	FR	3810-74-0	1-Jan-91	
Streptozocin (streptozotocin)	Developmental, female, male	FR	18883-66-4	20-Aug-99	
Streptozotocin (streptozocin)	cancer	SQE	18883-66-4	1-Jan-88	0.006
Strong inorganic acid mists containing sulfuric acid	cancer	A.B.	---	14-Mar-03	
Styrene	cancer	A.B.	100-42-5	22-Apr-16	27
Styrene oxide	cancer	SQE	96-09-3	1-Oct-88	4
Sulfallate	cancer	SQE	95-06-7	1-Jan-88	4
Sulfasalazine (Salicylazosulfapyridine)	cancer	A.B.	599-79-1	15-May-98	
Sulfasalazine (Salicylazosulfapyridine)	male	FR	599-79-1	29-Jan-99	
Sulfur dioxide ^e	developmental	SQE	7446-09-5	29-Jul-11	10000
Sulindac	Developmental, female	FR	38194-50-2	29-Jan-99	
Talc containing asbestiform fibers	cancer	A.B.	---	1-Apr-90	
Tamoxifen and its salts	cancer	SQE	10540-29-1	1-Sep-96	
Tamoxifen citrate	developmental	FR	54965-24-1	1-Jul-90	
Temazepam	developmental	FR	846-50-4	1-Apr-90	
Teniposide	developmental	FR	29767-20-2	1-Sep-96	
Terbacil	developmental	A.B.	5902-51-2	18-May-99	
Teriparatide	cancer	FR	52232-67-4	14-Aug-15	
Terrazole	cancer	A.B.	2593-15-9	1-Oct-94	
Testosterone and its esters	cancer	SQE	58-22-0	1-Apr-88	
Testosterone cypionate	developmental	FR	58-20-8	1-Oct-91	
Testosterone enanthate	developmental	FR	315-37-7	1-Apr-90	
Tetrabromobisphenol A	cancer	LC	79-94-7	27-Oct-17	
3,3',4,4'-Tetrachloroazobenzene	cancer	A.B.	14047-09-7	24-Jul-12	
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	cancer	SQE	1746-01-6	1-Jan-88	0.000005
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	developmental	A.B.	1746-01-6	1-Apr-91	
1,1,1,2-Tetrachloroethane	cancer	LC	630-20-6	13-Sep-13	
1,1,2,2-Tetrachloroethane	cancer	A.B.	79-34-5	1-Jul-90	3
Tetrachloroethylene (Perchloroethylene)	cancer	SQE	127-18-4	1-Apr-88	14
pa,a,a- Tetrachlorotoluene	cancer	A.B.	5216-25-1	1-Jan-90	
Tetrachlorvinphos	cancer	LC	22248-79-9	20-May-16	

Tetracycline (internal use)	developmental	FR	60-54-8	1-Oct-91	
Tetracyclines (internal use)	developmental	FR	---	1-Oct-92	
Tetracycline hydrochloride (internal use)	developmental	FR	64-75-5	1-Jan-91	
Tetrafluoroethylene	cancer	A.B.	116-14-3	1-May-97	
Δ^9 -Tetrahydrocannabinol (Δ^9 -THC)	developmental	SQE		3-Jan-20	
Tetrahydrofuran	cancer	LC	109-99-9	17-Dec-21	
Tetranitromethane	cancer	A.B.	509-14-8	1-Jul-90	0.059
Thalidomide	developmental	SQE	50-35-1	1-Jul-87	
Thioacetamide	cancer	SQE	62-55-5	1-Jan-88	0.1
4,4'-Thiodianiline	cancer	SQE	139-65-1	1-Apr-88	0.05
Thiodicarb	cancer	A.B.	59669-26-0	20-Aug-99	
Thioguanine	developmental	FR	154-42-7	1-Jul-90	
Thiophanate methyl	Female, Male	A.B.	23564-05-8	18-May-99	600 (oral)
Thiouracil	cancer		141-90-2	11-Jun-04	
Thiourea	cancer	SQE	62-56-6	1-Jan-88	10
Thorium dioxide	cancer	LC	1314-20-1	27-Feb-87	
Titanium dioxide (airborne, unbound particles of respirable size)	cancer	LC	---	2-Sep-11	
Tobacco, oral use of smokeless products	cancer	SQE	---	1-Apr-88	
Tobacco smoke	cancer	SQE	---	1-Apr-88	
Tobacco smoke (primary)	Developmental, female, male	SQE	---	1-Apr-88	
Tobramycin sulfate	developmental	FR	49842-07-1	1-Jul-90	
Toluene	developmental	SQE	108-88-3	1-Jan-91	7000 ^c
Toluene diisocyanate	cancer	LC	26471-62-5	1-Oct-89	20
o-Toluidine	cancer	SQE	95-53-4	1-Jan-88	4
o-Toluidine hydrochloride	cancer	SQE	636-21-5	1-Jan-88	5
Topiramate	developmental	FR	97240-79-4	27-Nov-15	
Toxaphene (Polychlorinated camphenes)	cancer	SQE	8001-35-2	1-Jan-88	0.6
Toxins derived from <i>Fusarium moniliforme</i> (<i>Fusarium verticillioides</i>)	cancer	LC	---	7-Aug-09	
Treosulfan	cancer	LC	299-75-2	27-Feb-87	
Triadimefon	Developmental, female, male	A.B.	43121-43-3	30-Mar-99	
Triamterene	cancer	LC	396-01-0	18-Apr-14	
Triazolam	developmental	FR	28911-01-5	1-Apr-90	
S,S,S-Tributyl phosphorotrithioate (Tribufos, DEF)	cancer	A.B.	78-48-8	25-Feb-11	
Tributyltin methacrylate	developmental	A.B.	2155-70-6	1-Dec-99	
Trichlormethine (Trimustine hydrochloride)	cancer	A.B.	817-09-4	1-Jan-92	
Trichloroacetic acid	cancer	LC	76-03-9	13-Sep-13	9.9
1,1,1-Trichloroethane	cancer	LC	71-55-6	21-Apr-23	
Trichloroethylene	cancer	SQE	79-01-6	1-Apr-88	14 (oral) 50 (inhalation)
Trichloroethylene	Developmental, male	A.B.	79-01-6	31-Jan-14	
2,4,6-Trichlorophenol	cancer	SQE	88-06-2	1-Jan-88	10
1,2,3-Trichloropropane	cancer	A.B.	96-18-4	1-Oct-92	
Trientine hydrochloride	developmental	FR	38260-01-4	27-Feb-01	
Triforine	developmental	A.B.	26644-46-2	18-Jun-99	
Trilostane	developmental	FR	13647-35-3	1-Apr-90	
Trimethadone	developmental	FR	127-48-0	1-Jan-91	
2,4,5-Trimethylaniline and its strong acid salts	cancer	SQE	---	24-Oct-97	
Trimethylolpropane triacrylate, tech	cancer	LC	---	17-Dec-21	
Trimethyl phosphate	cancer	A.B.	512-56-1	1-May-96	24
Trimetrexate glucuronate	developmental	FR	82952-64-5	26-Aug-97	
TRIM® VX	cancer	A.B.	---	25-May-18	
2,4,6-Trinitrotoluene (TNT)	cancer	SQE	118-96-7	19-Dec-08	8.2
Triphenyltin hydroxide	cancer	A.B.	76-87-9	1-Jul-92	
Triphenyltin hydroxide	developmental	A.B.	76-87-9	18-Mar-02	
Tris(1-aziridinyl)phosphine sulfide (Thiotepa)	cancer	SQE	52-24-4	1-Jan-88	0.06
Tris(2-chloroethyl) phosphate	cancer	A.B.	115-96-8	1-Apr-92	
Tris(2,3-dibromopropyl)phosphate	cancer	SQE	126-72-7	1-Jan-88	0.3
Tris(1,3-dichloro-2-propyl) phosphate (TDCPP)	cancer	SQE	13674-87-8	28-Oct-11	5.4
Trp-P-1 (Tryptophan-P-1)	cancer	SQE	62450-06-0	1-Apr-88	0.03
Trp-P-2 (Tryptophan-P-2)	cancer	SQE	62450-07-1	1-Apr-88	0.2
Trypan blue (commercial grade)	cancer	LC	72-57-1	1-Oct-89	

Unleaded gasoline (wholly vaporized)	cancer	SQE	---	1-Apr-88	
Uracil mustard	cancer	SQE	66-75-1	1-Apr-88	
Uracil mustard	Developmental, female, male	FR	66-75-1	1-Jan-92	
Urethane (Ethyl carbamate)	cancer	SQE	51-79-6	1-Jan-88	0.7
Urethane (Ethyl carbamate)	developmental	A.B.	51-79-6	1-Oct-94	
Urofollitropin	developmental	FR	97048-13-0	1-Apr-90	
Valproate (Valproic acid)	developmental	SQE	99-66-1	1-Jul-87	
Vanadium pentoxide (orthorhombic crystalline form)	cancer	<u>A.B.</u>	1314-62-1	11-Feb-05	
Vinblastine sulfate	developmental	FR	143-67-9	1-Jul-90	
Vinclozolin [basis for listing changed on November 16, 2006]	cancer	SQE	50471-44-8	20-Aug-99	
Vinclozolin	developmental	<u>A.B.</u>	50471-44-8	15-May-98	
Vincristine sulfate	developmental	FR	2068-78-2	1-Jul-90	
Vinyl bromide	cancer	SQE	593-60-2	1-Oct-88	
Vinyl chloride	cancer	LC	75-01-4	27-Feb-87	3
4-Vinylcyclohexene	cancer	A.B.	100-40-3	1-May-96	
4-Vinylcyclohexene [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female	<u>SQE</u>	100-40-3	7-Aug-09	
4-Vinyl-1-cyclohexene diepoxide	cancer	A.B.	106-87-6	1-Jul-90	
Vinyl cyclohexene dioxide (4-Vinyl-1-cyclohexene diepoxide) [Click here for the basis for the removal of male reproductive endpoint, effective December 20, 2013]	female	<u>SQE</u>	106-87-6	1-Aug-08	
Vinyl fluoride	cancer	<u>A.B.</u>	75-02-5	1-May-97	
Vinylidene chloride (1,1-Dichloroethylene)	cancer	<u>LC</u>	75-35-4	29-Dec-17	0.88
Vinyl trichloride (1,1,2-Trichloroethane)	cancer	A.B.	79-00-5	1-Oct-90	10
Vismodegib	Developmental, female, male	FR	879085-55-9	27-Jan-17	
Warfarin	developmental	SQE	81-81-2	1-Jul-87	
Wood dust	cancer	<u>LC</u>	---	18-Dec-09	
2,6-Xylidine (2,6-Dimethylaniline)	cancer	A.B.	87-62-7	1-Jan-91	110
Zalcitabine	cancer	<u>LC</u>	7481-89-2	7-Aug-09	
Zidovudine (AZT)	cancer	<u>LC</u>	30516-87-1	18-Dec-09	
	Cancer, Developmental, Female	<u>FR</u>	111406-87-2	22-Dec-00	